Analyst Price Targets — VCEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2026 5:07 pm | Caitlin Cronin | Canaccord Genuity | $60.00 | $47.93 | StreetInsider | Vericel Corporation (VCEL) PT Raised to $60 at Canaccord |
| July 16, 2026 2:08 pm | Richard Newitter | Truist Financial | $54.00 | $47.88 | TheFly | Vericel price target raised to $54 from $42 at Truist |
| May 8, 2026 10:17 am | — | H.C. Wainwright | $70.00 | $35.13 | TheFly | Vericel price target raised to $70 from $64 at H.C. Wainwright |
| April 15, 2026 12:45 pm | — | Truist Financial | $42.00 | $35.21 | TheFly | Vericel price target lowered to $42 from $48 at Truist |
| March 10, 2026 7:55 pm | Mike Kratky | Leerink Partners | $46.00 | $33.40 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Vericel Corporation (VCEL) following conference |
| December 18, 2025 2:16 pm | Richard Newitter | Truist Financial | $45.00 | $36.42 | TheFly | Vericel price target lowered to $45 from $50 at Truist |
| October 15, 2025 12:48 pm | — | Truist Financial | $41.00 | $34.50 | TheFly | Vericel price target lowered to $41 from $46 at Truist |
| December 18, 2024 12:32 pm | Richard Newitter | Truist Financial | $67.00 | $56.25 | TheFly | Vericel price target raised to $67 from $61 at Truist |
| August 26, 2024 9:33 am | Ryan Zimmerman | BTIG | $55.00 | $50.05 | StreetInsider | BTIG Reiterates Buy Rating on Vericel Corporation (VCEL) |
| August 2, 2024 6:07 am | Swayampakula Ramakanth | H.C. Wainwright | $60.00 | $47.52 | TheFly | Vericel price target raised to $60 from $55 at H.C. Wainwright |
Latest News for VCEL
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle…
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.
Canada Pension Plan Investment Board purchased a new position in Vericel Corporation (NASDAQ: VCEL) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 13,400 shares of the biotechnology company's stock, valued at approximately $596,000. Several other hedge funds and other institutional investors also recently
Bank of America Corp DE boosted its holdings in Vericel Corporation (NASDAQ: VCEL) by 19.7% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 1,098,771 shares of the biotechnology company's stock after buying an additional 180,761 shares during the period. Bank of America Corp DE owned
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VCEL.
U.S. House Trading
No House trades found for VCEL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.